Each week we spotlight one of our DigitalHealth.London businesses, founders or NHS fellows. Today, to commemorate World Liver Day, we are delighted to introduce CyberLiver, our current company DigitalHealth.London Accelerator.
What is the problem you are trying to solve and why is it important?
Liver diseases have seen their mortality rate quadruple over the last forty years. The situation, costing the health sector £3 billion, is exacerbated by alcohol abuse in the UK, which leads to one million hospital admissions a year and £21 billion in societal costs. By 2030, liver disease is expected to become one of the top three health problems in the UK, a challenge intensified by a projected 35 per cent deficit in specialist care. This convergence of factors highlights the urgent need for effective solutions to address the growing liver disease crisis.
Current treatment approaches for liver diseases are primarily reactive and fail to effectively treat warning signs, often leading to delayed diagnoses, prolonged hospital stays, and increased healthcare costs. The lack of effective pharmacological treatments also worsens the economic burden on the health system and reduces the quality of life of patients. There is an urgent need to evolve towards more proactive and scalable healthcare solutions to manage and mitigate the increasing prevalence and impact of liver disease in the UK, which is the mission CyberLiver is committed to fill.
What is the solution you have developed and how can it help solve the problem?
CyberLiver has developed an innovative digital medicine platform that leverages advanced liver clinical research, sensor technology, machine learning and artificial intelligence to transform liver disease management. Our platform is modular and configurable, designed to provide real-time comprehensive monitoring, diagnosis, treatment and management for a range of liver conditions.
By adopting our platform, healthcare providers can move from a reactive to a proactive care model, enabling early detection and intervention in the progression of liver disease. This approach aims to stop or even reverse the progression of liver diseases and significantly improve the quality of life of patients. Our technology also offers the potential to reduce healthcare costs by minimizing the need for hospitalizations and extensive medical interventions, which are often the result of late-stage disease diagnosis.
What is the history of your company?
The creation of CyberLiverr is based on a convergence of expertise and a shared commitment to transform the management of liver diseases. The journey began when our Chief Medical Officer, with over three decades of clinical practice, highlighted the gaps and inefficiencies in current care pathways for patients with liver disease. His ideas resonated with our co-founders, who had deep experience in digital health technologies and a shared commitment to addressing healthcare challenges.
Driven by a shared vision, this fusion of clinical wisdom and technological prowess laid the foundation for our company. The team, united by the determination to innovate and make meaningful impact, saw an opportunity to harness technological advancements to revolutionize the management of liver disease.
What successes have you had so far through successful pilots/trials/contracts?
We have achieved compelling results in clinical trials and real-world implementations. At the Royal Free Hospital in London, trials found that our medical devices can reduce payer costs by more than 30 percent, increase the efficiency of healthcare providers by 30 percent and significantly improve the quality of life of patients, with an engagement rate between 60 and 85 percent. . Building on this success, our devices are now part of a real-world implementation study across 20 NHS hospitals, a project funded by £4 million in grants from the National Institute for Health Research (NIHR).
Additionally, our digital medical devices are UKCA Class IIa marked and recognized by prestigious global health and innovation organizations. These include Innovate UK, the NIHR, DigitalHealth.London, the European Union (which awarded us the Seal of Excellence) and the United States Food and Drug Administration (USFDA), which granted us the Breakthrough Device designation. Such endorsements not only validate our technological advancements, but also highlight our commitment to providing effective healthcare solutions.
What are your future goals? What does success look like?
Our goal is to make AlcoChange an integral part of the healthcare ecosystem, especially for people facing alcohol-related problems. We are working to secure commissioning through NHS England, ensuring AlcoChange is accessible across primary care, secondary care and community settings, providing comprehensive reach. For us, success means empowering patients with our medical devices, enabling early detection of liver complications and promoting proactive management. This approach aims to stop or reverse the progression of liver disease, thereby significantly improving patients’ quality of life.
How has your time at the DigitalHealth.London Accelerator helped you achieve these goals?
The DigitalHealth.London Accelerator has played a crucial role in establishing valuable links with hospitals and integrated care systems (ICS) in London, giving us access to expert advisors and key healthcare stakeholders. Networking opportunities, along with support from a dedicated NHS Navigator, were instrumental in helping us understand the landscape and identify opportunities.
Additionally, the programme’s webinars and workshops have significantly increased our understanding of NHS procurement processes, allowing us to refine our strategies to meet NHS standards. This educational component of the Accelerator has been critical to improving our ability to develop compelling business cases for our technology.
Do you have any advice for future digital health companies?
Engaging with stakeholders at an early stage is essential to validate clinical and business pathways. Choosing the right early adopters and building strong relationships with them can provide critical insights, which are instrumental in shaping and refining solutions to meet real-world requirements.
Any requests for the public?
As innovators, we are committed to fostering collaboration to accelerate the progress of our innovative solutions, ultimately aiming to benefit patients and the healthcare system. We encourage other innovators, healthcare organizations and industry partners to join us collaboratively, working together toward our common goal of delivering meaningful benefits.
If you would like to learn more about our work or explore partnership opportunities, please contact us at info@cyberliver.com.
CyberLiver is currently part of Cohort 7 of the DigitalHealth.London Accelerator program.
THE DigitalHealth.London Accelerator The program is funded by the UK government through the UK Shared Prosperity Fund (UKSPF). It is delivered by the Health Innovation Network (HIN) South London in partnership with the Office of Life Sciences, CW+, Medicity, NHS England, the Mayor of London and the Leveling Up Fund.
For more information, please visit https://www.gov.uk/government/publications/uk-
Shared Prosperity Fund prospectus.
